What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist with established clinical use. Different brands contain the same active ingredient but are authorised for different indications and should not be treated as interchangeable without professional advice.
Approved-use context
Authorised liraglutide products include treatment of type 2 diabetes and weight management in defined groups alongside diet and physical activity. Eligibility and age criteria depend on the product and jurisdiction.
How it works
Liraglutide mimics GLP-1 activity, supporting glucose-dependent insulin secretion, reducing inappropriate glucagon secretion, slowing gastric emptying and influencing appetite.
Formulations and schedules
Liraglutide is supplied in multi-dose pre-filled pens for subcutaneous administration. It is generally associated with a daily schedule, but AEVLI does not provide dosing or titration instructions.
Useful information to track
- Daily administration record
- Weight or glucose trends requested by a clinician
- Digestive symptoms and hydration
- Pen start date and remaining supply
- Clinical review dates
Important safety considerations
- Gastrointestinal effects are common, particularly during treatment changes
- Persistent vomiting or diarrhoea may cause dehydration
- Symptoms suggestive of pancreatitis or gallbladder disease need medical assessment
- Hypoglycaemia can occur with certain other diabetes medicines
- Product storage and pen-use instructions must come from the official leaflet
Questions for a clinician or pharmacist
- Which liraglutide product has been prescribed?
- Which outcomes should be reviewed and when?
- What should I do if gastrointestinal effects persist?
- How should opened and unopened pens be stored?
Authoritative references
Regulatory status, warnings and availability can change. Check the current official product information for your country.